Smarter Decisions,
Better Care
UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.
For more information, click below.
Subscribers log in here
Related articles
Topic Outline
INTRODUCTION
Preoperative autologous donation (PAD) is the most popular and widely used of the autologous options, which also include preoperative hemodilution and blood salvage. Interest in all forms of autologous transfusion, particularly PAD, mushroomed in response to the AIDS epidemic, beginning as early as 1983. By 1993, when participation in PAD peaked, approximately 6 percent of all blood collected in the United States was collected for autologous use. (See "Acute normovolemic intraoperative hemodilution" and "Intraoperative and postoperative blood salvage".)
BENEFITS
The most obvious benefit of PAD for the donor/patient is freedom from concern about infectivity of the blood. Assuming that the donor is not bacteremic at the time of donation and/or there are no clerical errors resulting in the inadvertent transfusion of the wrong unit of blood, the patient is also protected against hemolytic, febrile or allergic transfusion reactions; alloimmunization to erythrocyte, leukocyte, platelet or protein antigens; and graft-versus-host disease (GVHD). (See "Transfusion-associated graft-versus-host disease".)
An additional benefit is that erythropoiesis may be stimulated by repeated phlebotomies, thereby enabling the patient to regenerate hemoglobin at an accelerated rate after surgery.
The overall efficacy of PAD has been evaluated in both randomized trials and cohort studies [1]. A meta-analysis found that patients who underwent PAD were much less likely than controls to receive allogeneic blood (odds ratio 0.17) but were more likely to undergo any transfusion with autologous and/or allogeneic blood (odds ratio 3.0) [2]. The latter effect is due both to a lower hematocrit in patients undergoing PAD and a more liberal transfusion policy when using autologous blood.
DRAWBACKS
PAD programs are not without some drawbacks. Perhaps the most important is that autologous blood is considerably more expensive than allogeneic blood. This problem is compounded by the fact that current reimbursement programs (including Medicare) either deny the medical necessity of PAD or ignore the well-documented increase in cost [3].
Subscribers log in here